Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-γ inducible protein 10 (IP-10) and its receptor CXCR3

Journal of Neuroimmunology

Volumn 209, Issue 1-2, 2009, Pages 87-95

  Feferman, Tali ^a   Aricha, Revital ^a   Mizrachi, Keren ^a,b   Geron, Erez ^a   Alon, Ronen ^a   Souroujon, Miriam C ^a,c   Fuchs, Sara ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

CXCR3; Experimental autoimmune myasthenia gravis (EAMG); IFN inducible protein 10 (IP 10); Immunosuppression; Myasthenia gravis (MG)

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10 ANTIBODY; POLYCLONAL ANTIBODY; T 487; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MODEL; FEMALE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES; CHEMOKINE CXCL10; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECEPTORS, CXCR3; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 64549137203     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.01.021     Document Type: Article

References (53)

1. Aharonov A., Tarrab-Hazdai R., Silman I., and Fuchs S. Immunochemical studies on acetylcholine receptor fraction from Torpedo californica. Immunochemistry 14 (1977) 129-137
2. Aricha R., Feferman T., Souroujon M.C., and Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. Faseb J. 20 (2006) 374-376
3. Baker M.S., Chen X., Rotramel A.R., Nelson J.J., Lu B., Gerard C., Kanwar Y., and Kaufman D.B. Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery 134 (2003) 126-133
4. Balashov K.E., Rottman J.B., Weiner H.L., and Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6873-6878
5. Bradding P., Walls A.F., and Holgate S.T. The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 117 (2006) 1277-1284
6. Bradley L.M., Asensio V.C., Schioetz L.K., Harbertson J., Krahl T., Patstone G., Woolf N., Campbell I.L., and Sarvetnick N. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J. Immunol. 162 (1999) 2511-2520
7. Chen W., Li H., Jia Y., Lv M., Li M., Feng P., Hu H., and Zhang L. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J. Autoimmun. 28 (2007) 30-40
8. Deurloo D.T., Chaudhary M.N., Olkiewicz K.M., Silva I.A., Choi S.W., Liu C., Collins T.L., Sullivan T.J., and Cooke K.R. A small molecular weight antagonist of CXCR3 reduces the severity of experimental idiopathic pneumonia syndrome and improves survival following allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 13 (2007) 105
9. Donnelly L.E., and Barnes P.J. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol. Sci. 27 (2006) 546-553
10. English D., and Andersen B.R. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J. Immunol. Methods 5 (1974) 249-252
11. Feferman T., Maiti P.K., Berrih-Aknin S., Bismuth J., Bidault J., Fuchs S., and Souroujon M.C. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J. Immunol. 174 (2005) 5324-5331
12. Fife B.T., Kennedy K.J., Paniagua M.C., Lukacs N.W., Kunkel S.L., Luster A.D., and Karpus W.J. CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 166 (2001) 7617-7624
13. Flier J., Boorsma D.M., van Beek P.J., Nieboer C., Stoof T.J., Willemze R., and Tensen C.P. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J. Pathol. 194 (2001) 398-405
14. Goldberg S.H., van der Meer P., Hesselgesser J., Jaffer S., Kolson D.L., Albright A.V., Gonzalez-Scarano F., and Lavi E. CXCR3 expression in human central nervous system diseases. Neuropathol. Appl. Neurobiol. 27 (2001) 127-138
15. Gottlieb A.B., Luster A.D., Posnett D.N., and Carter D.M. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J. Exp. Med. 168 (1988) 941-948
16. Hancock W.W., Lu B., Gao W., Csizmadia V., Faia K., King J.A., Smiley S.T., Ling M., Gerard N.P., and Gerard C. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J. Exp. Med. 192 (2000) 1515-1520
17. Hasegawa H., Inoue A., Kohno M., Muraoka M., Miyazaki T., Terada M., Nakayama T., Yoshie O., Nose M., and Yasukawa M. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis Rheum. 54 (2006) 1174-1183
18. Henneken M., Dorner T., Burmester G.R., and Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res. Ther. 7 (2005) R1001-1013
19. Im S.H., Barchan D., Fuchs S., and Souroujon M.C. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104 (1999) 1723-1730
20. Im S.H., Barchan D., Fuchs S., and Souroujon M.C. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J. Neuroimmunol. 111 (2000) 161-168
21. Janatpour M.J., Hudak S., Sathe M., Sedgwick J.D., and McEvoy L.M. Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. J. Exp. Med. 194 (2001) 1375-1384
22. Johnson M., Li A.R., Liu J., Fu Z., Zhu L., Miao S., Wang X., Xu Q., Huang A., Marcus A., Xu F., Ebsworth K., Sablan E., Danao J., Kumer J., Dairaghi D., Lawrence C., Sullivan T., Tonn G., Schall T., Collins T., and Medina J. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg. Med. Chem. Lett. 17 (2007) 3339-3343
23. Johnston B., Kim C.H., Soler D., Emoto M., and Butcher E.C. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J. Immunol. 171 (2003) 2960-2969
24. Kawauchi Y., Suzuki K., Watanabe S., Yamagiwa S., Yoneyama H., Han G.D., Palaniyandi S.S., Veeraveedu P.T., Watanabe K., Kawachi H., Okada Y., Shimizu F., Asakura H., Aoyagi Y., and Narumi S. Role of IP-10/CXCL10 in the progression of pancreatitis-like injury in mice after murine retroviral infection. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G345-354
25. Klein R.S., Izikson L., Means T., Gibson H.D., Lin E., Sobel R.A., Weiner H.L., and Luster A.D. IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J. Immunol. 172 (2004) 550-559
26. Lennon V.A., Lambert E.H., Leiby K.R., Okarma T.B., and Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146 (1991) 2245-2248
27. Liu L., Callahan M.K., Huang D., and Ransohoff R.M. Chemokine receptor CXCR3: an unexpected enigma. Curr. Top. Dev. Biol. 68 (2005) 149-181
28. -/- mice with experimental autoimmune encephalomyelitis. J. Immunol. 176 (2006) 4399-4409
29. Loetscher M., Gerber B., Loetscher P., Jones S.A., Piali L., Clark-Lewis I., Baggiolini M., and Moser B. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184 (1996) 963-969
30. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338 (1998) 436-445
31. Mach F., Sauty A., Iarossi A.S., Sukhova G.K., Neote K., Libby P., and Luster A.D. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104 (1999) 1041-1050
32. Matsumo Y., Sakuma H., Miyakoshi A., Tsukada Y., Kohyama K., Park I.K., and Tanuma N. Characterization of relapsing autoimmune encephalomyelitis and its treatment with decoy chemokine receptor genes. J. Neuroimmunol. 170 (2005) 49-61
33. Medina J. Discovery and Development of the CXCR3 Antagonist T487 as Therapy for Th1 Mediated Disorders. Presented at the 29th National Medicinal Chemistry Symposium (Madison, Wisconsin) (2004)
34. Menon R.T.R., Aricha R., Feferman T., Souroujon M.C., and Fuchs S. Suppression of Experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent. J. Neuroimmunol. (2008)
35. Mohan K., and Issekutz T.B. Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J. Immunol. 179 (2007) 8463-8469
36. Narumi S., Takeuchi T., Kobayashi Y., and Konishi K. Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine 12 (2000) 1561-1565
37. Narumi S., Kaburaki T., Yoneyama H., Iwamura H., Kobayashi Y., and Matsushima K. Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis. Eur. J. Immunol. 32 (2002) 1784-1791
38. Neville L.F., Mathiak G., and Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor. Rev. 8 (1997) 207-219
39. Patel D.D., Zachariah J.P., and Whichard L.P. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin. Immunol. 98 (2001) 39-45
40. Peled A., Kollet O., Ponomaryov T., Petit I., Franitza S., Grabovsky V., Slav M.M., Nagler A., Lider O., Alon R., Zipori D., and Lapidot T. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95 (2000) 3289-3296
41. Qin S., Rottman J.B., Myers P., Kassam N., Weinblatt M., Loetscher M., Koch A.E., Moser B., and Mackay C.R. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101 (1998) 746-754
42. Salomon I., Netzer N., Wildbaum G., Schif-Zuck S., Maor G., and Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppresses ongoing adjuvant arthritis. J. Immunol. 169 (2002) 2685-2693
43. Sasaki S., Yoneyama H., Suzuki K., Suriki H., Aiba T., Watanabe S., Kawauchi Y., Kawachi H., Shimizu F., Matsushima K., Asakura H., and Narumi S. Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur. J. Immunol. 32 (2002) 3197-3205
44. Sindern E., Patzold T., Ossege L.M., Gisevius A., and Malin J.P. Expression of chemokine receptor CXCR3 on cerebrospinal fluid T-cells is related to active MRI lesion appearance in patients with relapsing-remitting multiple sclerosis. J. Neuroimmunol. 131 (2002) 186-190
45. -/- mice. J. Immunol. 171 (2003) 1401-1406
46. Sorensen T.L., Tani M., Jensen J., Pierce V., Lucchinetti C., Folcik V.A., Qin S., Rottman J., Sellebjerg F., Strieter R.M., Frederiksen J.L., and Ransohoff R.M. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 103 (1999) 807-815
47. Suzaki Y., Hamada K., Nomi T., Ito T., Sho M., Kai Y., Nakajima Y., and Kimura H. A small-molecule compound targeting CCR5 and CXCR3 prevents the development of asthma. Eur. Respir. J (2007)
48. Tsubaki T., Takegawa S., Hanamoto H., Arita N., Kamogawa J., Yamamoto H., Takubo N., Nakata S., Yamada K., Yamamoto S., Yoshie O., and Nose M. Accumulation of plasma cells expressing CXCR3 in the synovial sublining regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts. Clin. Exp. Immunol. 141 (2005) 363-371
49. Uguccioni M., Gionchetti P., Robbiani D.F., Rizzello F., Peruzzo S., Campieri M., and Baggiolini M. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am. J. Pathol. 155 (1999) 331-336
50. van Wanrooij E.J., de Jager S.C., van Es T., de Vos P., Birch H.L., Owen D.A., Watson R.J., Biessen E.A., Chapman G.A., van Berkel T.J., and Kuiper J. CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor deficient mice. Arterioscler. Thromb. Vasc. Biol (2007)
51. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., Johnson M.G., Medina J.C., Collins T.L., and Fulton A.M. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66 (2006) 7701-7707
52. Wojcik W.J., Swoveland P., Zhang X., and Vanguri P. Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of lewis rat. J. Pharmacol. Exp. Ther. 278 (1996) 404-410
53. Yang H., Tuzun E., Alagappan D., Yu X., Scott B.G., Ischenko A., and Christadoss P. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1. J. Immunol. 175 (2005) 2018-2025